Lunch and Learn Series to Begin on 7 October
Our Lunch and Learn series is starting today and we will be hosting StemBioSys, Inc...
Caltag Medsystems offers many solutions for researchers working in the toxicology field.
With research areas including in-vitro absorption, distribution, metabolism and excretion (ADME) applications; innovative modes of culture; hepatotoxicity screening and mechanistic testing applications; infectious disease; and drug metabolism studies, the company provides the HepaRG cell line and options for quantifying Cytochrome P450 (CYP) in drug-drug interactions as tools to further research in these areas.
Through its suppliers, Caltag Medsystems offers hepatocyte cell line HepaRG™.
HepaRG™ cells have unique properties. They maintain hepatocyte functions while supporting the complete replicative cycle of the Hepatitis B Virus (HBV). This means they can be used in toxicology studies as an alternative to fresh hepatocytes. The HepaRG™ cell line can be used in a wide range of applications.
HepaRG™ has many key advantages over fresh hepatocytes and other hepatic cell lines, including:
For those customers working on drug metabolism, Caltag Medsystems can provide Silensomes™. Drug-drug interaction can significantly impact drug safety and efficacy. Prediction of this risk of drug-drug interactions is a requisite in the development of a new drug candidate.
In-vitro identification and measurement of the contribution of the major cytochrome P450 enzymes involved in the human metabolism of a new drug candidate, also called CYP phenotyping, helps predict the impact of co-administered drugs (perpetrators) on the pharmacokinetics of the new chemical entity (victims).
Until now, a battery of in-vitro tests recommended by the regulatory agencies such as the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) are required for this CYP phenotyping assay. These tests (correlation analysis, antibody or chemical inhibition and metabolism by recombinant human enzymes) have a number of disadvantages:
To overcome the disadvantages of the current methodologies, our supplier has developed in a patented new in-vitro drug development model. Silensomes™ are a single unique and representative model, capable of directly quantifying and predicting the contribution of CYP enzymes in drug metabolism. Silensomes™ are human pooled liver microsomes (HLMs) in which one specific CYP has been chemically knocked out (1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, 3A4).
Each Silensomes™ is available ready-to-use with each showing high specificity and efficiency of their targeted CYP inhibition (>80%) and only minor impact (<20%).
The key advantages of Silensomes™ include:
Contact Caltag Medsystems to learn more about these exciting products.
Our Lunch and Learn series is starting today and we will be hosting StemBioSys, Inc...
Caltag Medsystems offers ready to use cryopreserved cells, prepared in single bulk batches.
Renovos offers unique bone marrow mesenchymal stem cells (MSC), which have been isolated from patients...
Caltag Medsystems specialises in procuring haematopoietic cells collected from healthy and diseased donors. Its suppliers...